Please assess the completion status of the following clinical trial:

Trial Title: L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Experimental Siblings with MELAS (A3243G) syndrome~* 17-23 years~* Followed Neurometabolic Clinic at the Hospital for Sick Children will be studied.~* Normal electrolytes, glucose, renal and liver functions \& no history of gastrointestinal, respiratory or cardiac problems.~Controls~-Aged 17-23- Sex matched to the MELAS subjects~Exclusion Criteria:~Controls~* Experience migraines~* Have a metabolic disorder~* Taking medications predisposing to lactic acidosis or vasodilatation~* Neuromuscular/neurologic condition~* Cardiac or pulmonary disease~* Visual abnormalities~* Hypertension, anemia and prothrombotic state. Control subjects~* Contraindication for MRI (pacemaker, ocular metal, claustrophobia, tattoos) will be excluded from the study.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- MELAS Patients (Type: EXPERIMENTAL): Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
- Control Group (Type: NO_INTERVENTION): Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).